Patents Assigned to Ixogen Ltd.
  • Oncolytic adenoviruses with increased proportion of the 156R splicing isoform of the E1B protein
    Patent number: 10738283
    Abstract: The invention relates to a recombinant adenovirus that has an oncolytic effect in a cancer cell. By modulating the level and type of splice isoforms of the E1B gene product, expressed from the E1B gene, the oncolytic activity of such viruses can be enhanced. The invention provides a recombinant adenovirus in which the proportion of the E1B-156R isoform is increased relative to wild-type levels. Such a recombinant adenovirus may selectivity replicate in cancer cells, thereby killing cancer cells whilst sparing normal cells.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: August 11, 2020
    Assignee: Ixogen Ltd.
    Inventor: Hans Daniel Öberg
  • Oncolytic adenoviruses with increased proportion of the 156R splicing isoform of the E1B protein
    Patent number: 10047347
    Abstract: The invention relates to a recombinant adenovirus that has an oncolytic effect in a cancer cell. By modulating the level and type of splice isoforms of the E1B gene product, expressed from the E1B gene, the oncolytic activity of such viruses can be enhanced. The invention provides a recombinant adenovirus in which the proportion of the E1B-156R isoform is increased relative to wild-type levels. Such a recombinant adenovirus may selectivity replicate in cancer cells, thereby killing cancer cells while sparing normal cells.
    Type: Grant
    Filed: November 29, 2013
    Date of Patent: August 14, 2018
    Assignee: Ixogen Ltd.
    Inventor: Hans Daniel Öberg
  • ONCOLYTIC ADENOVIRUSES WITH INCREASED PROPORTION OF THE 156R SPLICING ISOFORM OF THE E1B PROTEIN
    Publication number: 20150315547
    Abstract: The invention relates to a recombinant adenovirus that has an oncolytic effect in a cancer cell. By modulating the level and type of splice isoforms of the E1B gene product, expressed from the E1B gene, the oncolytic activity of such viruses can be enhanced. The invention provides a recombinant adenovirus in which the proportion of the E1B-156R isoformis increased relative to wild-type levels. Such a recombinant adenovirus may selectivity replicate in cancer cells, thereby killing cancer cells whilst sparing normal cells.
    Type: Application
    Filed: November 29, 2013
    Publication date: November 5, 2015
    Applicant: Ixogen Ltd.
    Inventor: Hans Daniel Öberg